Lyon Joseph Douglas sold $1.2M of CORT

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.07 ($115.40–$116.54, $1.16M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lyon Joseph Douglas
Published Oct 5, 2026, 11:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 11:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale is the primary new fact; no other material news is present.

02

Market read

A modest insider sale that may cause slight short‑term pressure on CORT.

03

What to watch

Potential upcoming dilution or secondary offering that prompted the insider to reduce holdings.

Relevance 5/10Novelty 3/10Timing: post‑market filing on Oct 5

Background

Form 4 filing discloses insider transactions required by the SEC.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

Officer Lyon Joseph Douglas sold 10,000 shares for $1.16M via a 10b5‑1 plan.

Expected impact

likely modest downward pressure as the market prices the insider sale.

Evidence & confidence

A $1.2M sale by an officer is material but not large enough to drive a significant move; investors may view it as a neutral to slightly negative signal.

Market effects

None

None

None

Counterpoint

The sale could be a routine liquidity move unrelated to company fundamentals.

Key entities

  • Corcept Therapeutics Inc.

    Biopharma listed on NASDAQ under CORT.

  • Lyon Joseph Douglas

    Insider reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.